Trends and Patterns of Geographic Variation in Opioid Prescribing Practices by State, United States, 2006-2017
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Importance: Risk of opioid use disorder, overdose, and death from prescription opioids increases as dosage, duration, and use of extended-release and long-acting formulations increase. States are well suited to respond to the opioid crisis through legislation, regulations, enforcement, surveillance, and other interventions. Objective: To estimate temporal trends and geographic variations in 6 key opioid prescribing measures in 50 US states and the District of Columbia. Design, Setting, and Participants: Population-based cross-sectional analysis of opioid prescriptions filled nationwide at US retail pharmacies between January 1, 2006, and December 31, 2017. Data were obtained from the IQVIA Xponent database. All US residents who had an opioid prescription filled at a US retail pharmacy were included. Main Outcomes and Measures: Primary outcomes were annual amount of opioids prescribed in morphine milligram equivalents (MME) per person; mean duration per prescription in days; and 4 separate prescribing rates-for prescriptions 3 or fewer days, those 30 days or longer, those with a high daily dosage (≥90 MME), and those with extended-release and long-acting formulations. Results: Between 2006 and 2017, an estimated 233.7 million opioid prescriptions were filled in retail pharmacies in the United States each year. For all states combined, 4 measures decreased: (1) mean (SD) amount of opioids prescribed (mean [SD] decrease, 12.8% [12.6%]) from 628.4 (178.0) to 543.4 (158.6) MME per person, a statistically significant decrease in 23 states; (2) high daily dosage (mean [SD] decrease, 53.1% [13.6%]) from 12.3 (3.4) to 5.6 (1.7) per 100 persons, a statistically significant decrease in 49 states; (3) short-term (≤3 days) duration (mean [SD] decrease, 43.1% [9.4%]) from 18.0 (5.4) to 10.0 (2.5) per 100 persons, a statistically significant decrease in 48 states; and (4) extended-release and long-acting formulations (mean [SD] decrease, 14.7% [13.7%]) from 7.2 (1.9) to 6.0 (1.7) per 100 persons, a statistically significant decrease in 27 states. Two measures increased, each associated with the duration of prescription dispensed: (1) mean (SD) prescription duration (mean [SD] increase, 37.6% [6.9%]) from 13.0 (1.2) to 17.9 (1.4) days, a statistically significant increase in every state; and (2) prescriptions for a term of 30 days or longer (mean [SD] increase, 37.7% [28.9%]) from 18.3 (7.7) to 24.9 (10.7) per 100 persons, a statistically significant increase in 39 states. Two- to 3-fold geographic differences were observed across states, measured by comparing the ratio of each state's 90th to 10th percentile for each measure. Conclusions and Relevance: In this study, across 12 years, the mean duration and prescribing rate for long-term prescriptions of opioids increased, whereas the amount of opioids prescribed per person and prescribing rate for high-dosage prescriptions, short-term prescriptions, and extended-release and long-acting formulations decreased. Some decreases were significant, but results were still high. Two- to 3-fold state variation in 5 measures occurred in most states. This information may help when state-specific intervention programs are being designed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
Dowell, D., Haegerich, T. M., & Chou, R. (2016) · JAMA · doi:10.1001/jama.2016.1464 · Cited by 5,161
Chou, R., Gordon, D. B., de Leon-Casasola, O. A., Rosenberg, J. M., Bickler, S., Brennan, T., Carter, T., Cassidy, C. L., Chittenden, E. H., Degenhardt, E., et al. (2016) · The Journal of Pain · doi:10.1016/j.jpain.2015.12.008 · Cited by 3,171
Increases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859
Vital signs: changes in opioid prescribing in the United States, 2006-2015.
Guy, G. P., Zhang, K., Bohm, M. K., Losby, J., Lewis, B., Young, R., Murphy, L. B., & Dowell, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6626a4 · Cited by 1,117
Self-citationShah, A., Hayes, C. J., & Martin, B. C. (2017) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6610a1 · Cited by 954
Han, B., Compton, W. M., Blanco, C., Crane, E., Lee, J., & Jones, C. M. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0865 · Cited by 873
Overdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016.
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6712a1 · Cited by 821
Self-citationBrat, G. A., Agniel, D., Beam, A., Yorkgitis, B., Bicket, M., Homer, M., Fox, K. P., Knecht, D. B., McMahill-Walraven, C. N., Palmer, N., et al. (2018) · BMJ · doi:10.1136/bmj.j5790 · Cited by 591
Prescription of long-acting opioids and mortality in patients with chronic noncancer pain
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2016) · JAMA · doi:10.1001/jama.2016.7789 · Cited by 369
Dowell, D., Zhang, K., Noonan, R. K., & Hockenberry, J. M. (2016) · Health Affairs · doi:10.1377/hlthaff.2016.0448 · Cited by 264
Increased use of heroin as an initiating opioid of abuse
Cicero, T. J., Ellis, M. S., & Kasper, Z. A. (2017) · Addictive Behaviors · doi:10.1016/j.addbeh.2017.05.030 · Cited by 153
Research works printed but not linked: 23
- Dowell, 2017, Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000-2015., JAMA, 318, 1065, 10.1001/jama.2017.9308 · DOI · Paper page
- Scholl, 2018, Drug and opioid-involved overdose deaths—United States, 2013-2017., MMWR Morb Mortal Wkly Rep, 67, 1419, 10.15585/mmwr.mm675152e1 · DOI · Paper page
- Manchikanti, 2017, Responsible, safe, and effective prescription of opioids for chronic non-cancer pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines., Pain Physician, 20, S3, 10.36076/ppj.2017.s92 · DOI · Paper page
- Rosenberg, 2018, Opioid therapy for chronic pain: overview of the 2017 US Department of Veterans Affairs and US Department of Defense Clinical Practice Guideline., Pain Med, 19, 928, 10.1093/pm/pnx203 · DOI · Paper page
- Edlund, 2014, The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription., Clin J Pain, 30, 557, 10.1097/AJP.0000000000000021 · DOI · Paper page
- Paulozzi, 2014, Risk of adverse health outcomes with increasing duration and regularity of opioid therapy., J Am Board Fam Med, 27, 329, 10.3122/jabfm.2014.03.130290 · DOI · Paper page
- Centers for Disease Control and Prevention (CDC), 2012, Vital signs: risk for overdose from methadone used for pain relief—United States, 1999-2010., MMWR Morb Mortal Wkly Rep, 61, 493
- Miller, 2015, Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy., JAMA Intern Med, 175, 608, 10.1001/jamainternmed.2014.8071 · DOI · Paper page
- Zedler, 2014, Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients., Pain Med, 15, 1911, 10.1111/pme.12480 · DOI · Paper page
- Compton, 2016, Relationship between nonmedical prescription-opioid use and heroin use., N Engl J Med, 374, 154, 10.1056/NEJMra1508490 · DOI · Paper page
- Nuckols, 2014, Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain., Ann Intern Med, 160, 38, 10.7326/0003-4819-160-1-201401070-00732 · DOI · Paper page
- Kim, 2000, Permutation tests for Joinpoint regression with applications to cancer rates., Stat Med, 19, 335, 10.1002/(ISSN)1097-0258 · DOI
- Dwyer-Lindgren, 2016, US county-level trends in mortality rates for major causes of death, 1980-2014., JAMA, 316, 2385, 10.1001/jama.2016.13645 · DOI · Paper page
- Rutkow, 2017, More states should regulate pain management clinics to promote public health., Am J Public Health, 107, 240, 10.2105/AJPH.2016.303568 · DOI
- Lyapustina, 2016, Effect of a “pill mill” law on opioid prescribing and utilization: the case of Texas., Drug Alcohol Depend, 159, 190, 10.1016/j.drugalcdep.2015.12.025 · DOI
- Rutkow, 2015, Effect of Florida’s Prescription Drug Monitoring Program and pill mill laws on opioid prescribing and use., JAMA Intern Med, 175, 1642, 10.1001/jamainternmed.2015.3931 · DOI · Paper page
- Johnson, 2014, Decline in drug overdose deaths after state policy changes—Florida, 2010-2012., MMWR Morb Mortal Wkly Rep, 63, 569
- 2017, Optimizing the treatment of acute pain in the emergency department., Ann Emerg Med, 70, 446, 10.1016/j.annemergmed.2017.06.043 · DOI
- Seth, 2018, Quantifying the epidemic of prescription opioid overdose deaths., Am J Public Health, 108, 500, 10.2105/AJPH.2017.304265 · DOI · Paper page
- Mattson, 2018, Opportunities to prevent overdose deaths involving prescription and illicit opioids, 11 states, July 2016-June 2017., MMWR Morb Mortal Wkly Rep, 67, 945, 10.15585/mmwr.mm6734a2 · DOI
- Weiss, 2016, Opioid-Related Inpatient Stays and Emergency Department Visits by State, 2009–2014
- Muhuri, 2013, CBHSQ DataReview
- National Conference of State Legislatures. Prescribing policies: states confront opioid overdose epidemic. http://www.ncsl.org/research/health/prescribing-policies-states-confront-opioid-overdose-epidemic.aspx. Published October 31, 2018. Accessed January 23, 2019.
Cited by
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
The Lancet Series call to action to reduce low value care for low back pain: an update
Buchbinder, R., Underwood, M., Hartvigsen, J., & Maher, C. G. (2020) · Pain · doi:10.1097/j.pain.0000000000001869 · Cited by 290
Burke, L. G., Zhou, X., Boyle, K. L., Orav, E. J., Bernson, D., Hood, M., Land, T., Bharel, M., & Frakt, A. B. (2020) · Addiction · doi:10.1111/add.14867 · Cited by 35
Price-Haywood, E. G., Burton, J., Burstain, T., Harden-Barrios, J., Lefante, J., Shi, L., Jamison, R. N., Bazzano, A., & Bazzano, L. (2020) · Value in Health · doi:10.1016/j.jval.2019.09.2748 · Cited by 30
“0 per 100.[20] Most of the decline in Louisiana’s high-dose prescribing occurred between 2009 and 2012.”
BackgroundWhat Drives Risky Prescription Opioid Use? Evidence from Migration
Finkelstein, A., Gentzkow, M., Li, D., & Williams, H. (2022) · doi:10.3386/w30471 · Cited by 20
“There is wide geographic variation in the intensity of the opioid epidemic, with prescribing per capita varying by a factor of more than two between the 10th and 90th percentile states (McDonald, Carlson, and Izrael 2012; Schieber et al. 2019), and Appalachia, New England, and the West (Guy et al.”
Background
Metadata
- Authors
- Schieber, L. Z., Guy, G. P., Seth, P., Young, R., Mattson, C. L., Mikosz, C. A., & Schieber, R. A.
- Venue
- JAMA Network Open
- Publisher
- American Medical Association (AMA)
- Published
- 2019-03-15
- Volume
- 2
- Issue
- 3
- Pages
- e190665
- ISSN
- 2574-3805 (ISSN-L)
- OpenAlex
- W2922426486
- Cited by
- 251
- References
- 13
- FWCI
- 31.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.